Texas pharmacies are facing increasing scrutiny by the Board of Pharmacy, which is working closely with the DEA and other federal agencies, to investigate regulatory violations and Medicaid claims.

Pharmacies across Texas are facing heightened enforcement and increased scrutiny by the Texas Board of Pharmacy (“BOP”). In recent months, aggressive investigators have conducted surprise visits to pharmacies. In some cases, the BOP has gone so far as to ask pharmacists to surrender their license on the spot.

board investigation

If you are targeted by the BOP or other agency, it is critical to not say or do anything unless you fully understand the implications. In addition, it is always advisable to have a witness so investigators cannot twist statements to support their position.

Like PBM audits, your statements can be recorded and used against you. Therefore, before the underlying facts and circumstances become clear, it is advisable to not take a position on anything absent legal representation.

Likewise, get prepared. Don’t wait for an investigation to arise before you take steps to protect yourself. If you are aware of areas of potential concern, whatever they may be, let us help you address them.

In a highly regulated industry like healthcare, there are often grey areas around compliance. Although these areas present opportunities, some degree of risk comes with everything.

If and when someone disagrees with the approach your business has taken, all processes involved will be heavily scrutinized and tested. Your decision-making and compliance efforts likewise will be second-guessed.

In short, act proactively to insulate your livelihood from attack, whether that be from the Texas Board or any other regulator. And if you are already dealing with an investigation or discrepant PBM audit that could be referred to regulators, don't wait to take defensive action. Schedule a free consultation now.

Frequently Asked Questions

FTC Issues Interim Report Condemning Anticompetitive PBM Practices

The top Pharmacy Benefit Managers (PBMs) are condemned by the FTC for manipulating the healthcare system to generate significant profits, thereby inflating drug costs and overcharging patients, particularly for critical medications like cancer drugs.


Seized Ozempic Shipments Highlight Rising Demand and Safety Concerns

Ozempic, a well-known medication for type 2 diabetes, has gained popularity for its off-label use in weight loss, leading to increased scrutiny by authorities. Recently, U.S. Customs and Border Protection (CBP) officers in Cincinnati seized several shipments of the drug, underscoring the growing demand and associated risks.


A Golden Opportunity for Compounding Pharmacies: Navigating the Ozempic Shortage

There has never been a more fortunate time for compounding pharmacies looking to capitalize on the "Gold Rush" of Ozempic. Due to the forecasted limited supply of the brand name drug, the FDA has put Ozempic on the shortage list, which will allow for a more accommodating set of rules regarding compounding and distribution of semaglutide-based drugs.


Semaglutide Compliance Program: A Must Have

The semaglutide industry is relatively new, and significant regulatory enforcement typically lags by at least two years. Accordingly, all participants involved in the semaglutide supply chain should implement well-designed compliance programs now to reduce the risk and severity of future regulatory action.